Laurion Capital Management’s Heron Therapeutics HRTX Stock Holding History

Laurion Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-114,817	Closed	-$287K	–	470
2022 Q4	$287K	Buy	114,817 +496	+0.4%	+$1.6K	﹤0.01%	373
2022 Q3	$482K	Buy	+114,321	New	+$447K	﹤0.01%	404
2019 Q4	–	Sell	-24,624	Closed	-$456K	–	1022
2019 Q3	$456K	Buy	+24,624	New	+$453K	﹤0.01%	783
2019 Q2	–	Sell	-8,856	Closed	-$216K	–	1012
2019 Q1	$216K	Buy	+8,856	New	+$232K	﹤0.01%	741
2018 Q4	–	Sell	-87,103	Closed	-$2.76M	–	1235
2018 Q3	$2.76M	Buy	+87,103	New	+$3.24M	0.03%	478

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Laurion Capital Management's HRTX Position: Q1 2023 in Review

Laurion Capital Management sold out of Heron Therapeutics (HRTX) in Q1 2023, closing a stake of 114,817 shares — an estimated $287K sold.

Laurion Capital Management first reported a position in HRTX in Q3 2018 and held it in 5 quarters. The position peaked at $2.76M in Q3 2018. 162 funds tracked by Wall St. Rank hold HRTX as of Q1 2023.

Laurion Capital Management reported no remaining Heron Therapeutics position as of Q1 2023 after selling out during the quarter.
Laurion Capital Management sold 114,817 Heron Therapeutics shares in Q1 2023, an estimated $287K.
Laurion Capital Management first reported a position in Heron Therapeutics in Q3 2018 and held it in 5 quarters.
Laurion Capital Management's Heron Therapeutics position peaked at $2.76M in Q3 2018.
162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2023.

Based on Laurion Capital Management's 13F filing for Q1 2023, filed 15 May 2023.